Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer.

Neoplasia (New York, N.Y.)·2026
Same author

EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism.

Oncogene·2025
Same author

Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.

International journal of molecular sciences·2025
Same author

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.

International journal of molecular sciences·2024
Same author

Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells.

International journal of molecular sciences·2023
Same author

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

Cancers·2023

Related Experiment Video

Updated: May 9, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Mining sarcomas by proteomics approaches: Ewing sarcoma on the spotlight.

Carlos Mackintosh1, Juan Madoz-Gúrpide

  • 1Molecular Pathology Program, Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca- CSIC, Salamanca, 37007, Spain. cmackintosh@usal.es

Recent Patents on Biotechnology
|July 16, 2013
PubMed
Summary

Proteomics advances sarcoma research by identifying molecular targets and biomarkers. This high-throughput approach aids in diagnosing diverse sarcomas and developing novel therapies, particularly for Ewing sarcoma.

More Related Videos

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: May 9, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Sarcomas are diverse tumors of mesenchymal origin with varying diagnostic clarity.
  • Some sarcomas have identifiable molecular alterations, but others lack definitive diagnostic tools despite similar clinical presentations.
  • High-throughput technologies are crucial for molecularly classifying sarcoma subtypes.

Purpose of the Study:

  • To review the application of proteomics in understanding sarcoma biology.
  • To highlight the potential of proteomics in discovering diagnostic biomarkers and therapeutic targets.
  • To emphasize the role of proteomics in elucidating sarcoma subtype boundaries and treatment responses, with a focus on Ewing sarcoma.

Main Methods:

  • Review of current literature on proteomics applications in sarcoma research.
  • Focus on high-throughput proteomics strategies for molecular delineation.
  • Analysis of proteomics' contribution to understanding chimeric fusion proteins and their interactome.

Main Results:

  • Proteomics offers high-throughput capabilities for molecularly defining sarcoma subtypes.
  • Proteomics aids in identifying molecular targets of chimeric fusion proteins.
  • Proteomics facilitates the discovery of new biomarkers and therapeutic targets for sarcomas.

Conclusions:

  • Proteomics provides essential analytical power to decipher sarcoma biology.
  • This knowledge is vital for developing innovative diagnostic and therapeutic tools for sarcomas.
  • Future patents are anticipated based on proteomics-driven insights into sarcoma pathogenesis and treatment.